Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Eli Lilly and Company

NYSE

Market Cap.

767.39B

Avg. Volume

2.75M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Eli Lilly and Company!

Still processing it, give me a bit more time...

Eli Lilly and Company News

Eli Lilly and Company Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - General
lilly.com

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company Earnings & Revenue

Eli Lilly and Company Financials

Table Compare

Compare LLY metrics with:

   

Earnings & Growth

LLY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

LLY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

LLY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

LLY

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Eli Lilly and Company Income

Eli Lilly and Company Balance Sheet

Eli Lilly and Company Cash Flow

Eli Lilly and Company Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Eli Lilly and Company Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

4.8600

Payment DateDividendFrequency
2024-06-101.3Quarterly
2024-03-081.3Quarterly
2023-12-081.13Quarterly
2023-09-081.13Quarterly
2023-06-091.13Quarterly

Historical Market Cap

Shares Outstanding

Eli Lilly and Company Executives

NameRole
Mr. David A. RicksChairman, Chief Executive Officer & President
Dr. Daniel M. Skovronsky M.D., Ph.D.EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Ms. Anat AshkenaziExecutive Vice President & Chief Financial Officer
Ms. Anat Hakim J.D.Executive Vice President, General Counsel & Secretary
Mr. Jacob S. Van NaardenExecutive Vice President & President of Loxo
NameRoleGenderDate of BirthPay
Mr. David A. RicksChairman, Chief Executive Officer & PresidentMale19686.29M
Dr. Daniel M. Skovronsky M.D., Ph.D.EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology19743.82M
Ms. Anat AshkenaziExecutive Vice President & Chief Financial OfficerFemale19732.96M
Ms. Anat Hakim J.D.Executive Vice President, General Counsel & SecretaryFemale19692.81M
Mr. Jacob S. Van NaardenExecutive Vice President & President of LoxoMale19852.38M

Eli Lilly and Company Insider Trades

Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares6061
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares4886
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares3491
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares3917
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares2567
DateNameRoleTransactionTypeShares
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale6061
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale4886
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale3491
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale3917
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale2567

Discover More

Streamlined Academy

Eli Lilly and Company

NYSE

Market Cap.

767.39B

Avg. Volume

2.75M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Eli Lilly and Company News

Eli Lilly and Company Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Eli Lilly and Company Earnings & Revenue

Eli Lilly and Company Income

Eli Lilly and Company Balance Sheet

Eli Lilly and Company Cash Flow

Eli Lilly and Company Financials Over Time

Eli Lilly and Company Executives

NameRole
Mr. David A. RicksChairman, Chief Executive Officer & President
Dr. Daniel M. Skovronsky M.D., Ph.D.EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Ms. Anat AshkenaziExecutive Vice President & Chief Financial Officer
Ms. Anat Hakim J.D.Executive Vice President, General Counsel & Secretary
Mr. Jacob S. Van NaardenExecutive Vice President & President of Loxo
NameRoleGenderDate of BirthPay
Mr. David A. RicksChairman, Chief Executive Officer & PresidentMale19686.29M
Dr. Daniel M. Skovronsky M.D., Ph.D.EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology19743.82M
Ms. Anat AshkenaziExecutive Vice President & Chief Financial OfficerFemale19732.96M
Ms. Anat Hakim J.D.Executive Vice President, General Counsel & SecretaryFemale19692.81M
Mr. Jacob S. Van NaardenExecutive Vice President & President of LoxoMale19852.38M

Eli Lilly and Company Insider Trades

Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares6061
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares4886
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares3491
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares3917
Date23 May
NameLILLY ENDOWMENT INC
Role10 percent owner
TransactionDisposed
TypeS-Sale
Shares2567
DateNameRoleTransactionTypeShares
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale6061
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale4886
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale3491
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale3917
23 MayLILLY ENDOWMENT INC10 percent ownerDisposedS-Sale2567

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
lilly.com

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Eli Lilly and Company!

Still processing it, give me a bit more time...

Eli Lilly and Company Financials

Table Compare

Compare LLY metrics with:

   

Earnings & Growth

LLY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

LLY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

LLY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

LLY

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Eli Lilly and Company Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

4.8600

Payment DateDividendFrequency
2024-06-101.3Quarterly
2024-03-081.3Quarterly
2023-12-081.13Quarterly
2023-09-081.13Quarterly
2023-06-091.13Quarterly

Eli Lilly and Company Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More